Zoetis Inc

Chart & Performance

D1W1MN

P/E

31.62

P/S

8.67

EPS

5.20

Div Yield, %

0.93%

Shrs. gr., 5y

-1.03%

Rev. gr., 5y

7.96%

Revenues

8.54b

+5.74%

Net income

2.34b

+10.88%

CFO

2.35b

+23.06%

Dividend

Jul 18, 20240.432 USD/sh

Earnings

Feb 11, 2025

Profile

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

URL

https://www.zoetis.com/

IPO date

Feb 01, 2013

Employees

13,800

Domiciled in

Incorporated in

Valuation

Order:

Title USD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title USD in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	8,544,000 5.74%	8,080,000 3.91%	7,776,000 16.49%
Cost of revenue	5,475,000	5,002,000	4,812,000
Unusual Expense (Income)
NOPBT	3,069,000	3,078,000	2,964,000
NOPBT Margin	35.92%	38.09%	38.12%
Operating Taxes	596,000	545,000	454,000
Tax Rate	19.42%	17.71%	15.32%
NOPAT	2,473,000	2,533,000	2,510,000
Net income	2,344,000 10.88%	2,114,000 3.78%	2,037,000 24.36%
Dividends	(692,000)	(611,000)	(474,000)
Dividend yield	0.76%	0.89%	0.41%
Proceeds from repurchase of equity	(1,092,000)	(1,594,000)	(743,000)
BB yield	1.20%	2.31%	0.64%
Debt
Debt current	3,000	1,352,000	41,000
Long-term debt	6,940,000	6,924,000	6,894,000
Deferred revenue		9,000	257,000
Other long-term liabilities	508,000	466,000	239,000
Net debt	4,879,000	4,668,000	3,420,000
Cash flow
Cash from operating activities	2,353,000	1,912,000	2,213,000
CAPEX	(732,000)	(586,000)	(477,000)
Cash from investing activities	(777,000)	(883,000)	(458,000)
Cash from financing activities	(3,109,000)	(904,000)	(1,862,000)
FCF	1,596,000	1,742,000	2,053,000
Balance
Cash	2,041,000	3,577,000	3,482,000
Long term investments	23,000	31,000	33,000
Excess cash	1,636,800	3,204,000	3,126,200
Stockholders' equity	9,455,000	7,854,000	6,428,000
Invested Capital	10,617,200	9,607,000	8,659,800
ROIC	24.46%	27.73%	29.55%
ROCE	24.75%	23.76%	24.48%
EV
Common stock shares outstanding	462,269	470,385	476,717
Price	197.37 34.68%	146.55 -39.95%	244.03 47.45%
Market cap	91,238,033 32.35%	68,934,922 -40.74%	116,333,250 46.88%
EV	96,111,033	73,600,922	119,754,250
EBITDA	3,560,000	3,543,000	3,412,000
EV/EBITDA	27.00	20.77	35.10
Interest	239,000	221,000	224,000
Interest/NOPBT	7.79%	7.18%	7.56%